[Prognostic Factors and Survival in Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma: a MultiCenter...

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, with a five-year survival rate of less than 10%. Most patients are diagnosed at advanced stages, and both incidence and mortality are expected to rise over the next decade.

To estimate overall survival in patients undergoing surgery for pancreatic ductal adenocarcinoma and to analyze associated clinicopathological factors.

A multicenter, retrospective cohort study was condcuted. Patients who underwent surgery between January 2019 and December 2024 with histologically confirmed pancreatic ductal adenocarcinoma were included. Factors associated with overall survival were identified through multivariate analysis using Cox proportional hazards regression.

A total of 122 patients were evaluated. The mean age was 66.6 years, and 53.3% were female. Postoperative chemotherapy was administered in 62.3% of cases. The median overall survival was 31.7 months. Tumor recurrence occurred in 28.7% of patients, and 31.1% experienced postoperative complications. Multivariate analysis revealed that adjuvant chemotherapy was significantly associated with reduced mortality risk (HR 0.09; 95% CI: 0.04-0.21; p < 0.001). Tumor recurrence (HR 2.5; 95% CI: 1.25-5.03; p = 0.01) and histological tumor differentiation (HR 2.2; 95% CI: 1.214.00; p = 0.01) were associated with increased mortality.

Surgery combined with adjuvant chemotherapy is significantly associated with improved survival in patients with pancreatic ductal adenocarcinoma. Conversely, tumor recurrence and histological tumor differentiation are linked to decreased survival.